Jorge Andrade
About Jorge Andrade
Jorge Andrade is the Executive Director and Global Head of Bioinformatics and Genomics at Kite Pharma, Gilead Sciences, where he has worked since 2019. He has extensive experience in cancer genomics, drug discovery, and biomarker discovery, having held significant roles at various prestigious institutions including the University of Chicago and Beijing Genomics Institute.
Work at Kite Pharma
Jorge Andrade serves as the Executive Director and Global Head of Bioinformatics and Genomics at Kite Pharma, a Gilead Sciences company. He has held this position since 2019 in Santa Monica, California. In his role, he manages bioinformatics and genomics initiatives that support the development of innovative cancer therapies. His leadership focuses on integrating advanced data analysis techniques to enhance the understanding of cancer biology and improve patient outcomes.
Education and Expertise
Jorge Andrade has an extensive educational background in genomics, proteomics, and bioinformatics. He completed his PhD in Biotechnology at KTH Royal Institute of Technology from 2002 to 2007. He furthered his studies at Karolinska Institutet, where he achieved a Post-Doctoral position in 2007 to 2008. His expertise encompasses scientific research collaborations in cancer genomics, drug discovery, and biomarker discovery.
Background
Before joining Kite Pharma, Jorge Andrade held several significant positions in the field of bioinformatics and genomics. He worked as an Associate Director at the Beijing Genomics Institute from 2011 to 2012, where he led pharmacogenomics R&D efforts. He also served as a Research Scientist at Eli Lilly and Company in Singapore from 2008 to 2011 and as Director of Bioinformatics at the University of Chicago from 2012 to 2019.
Achievements
Jorge Andrade has made notable contributions to the field of bioinformatics and genomics. He led the Translational Xenograft Informatics System project, which focuses on predicting clinical outcomes. He represented Eli Lilly on the FDA’s Sequencing Quality Control (SEQC) Consortium and served as the scientific/project lead for the 'Cistrome' project in collaboration with Dana Farber Cancer Institute at Harvard University. His work includes developing pipelines for NGS-based studies and integrating gene expression and SNP arrays data.